Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9 billion rare disease expansion

Neurocrine Biosciences has agreed to purchase Soleno Therapeutics for $53.00 per share in cash. The $2.9 billion deal centers on VYKAT XR, a first-in-class treatment for Prader-Willi syndrome that generated $190 million in 2025, significantly bolstering Neurocrine’s endocrinology and rare disease portfolio.

Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics for an equity value of approximately $2.9 billion. Under the terms of the cash transaction, Soleno shareholders will receive $53.00 per share. Neurocrine Biosciences is a biopharmaceutical company focused on neuroendocrinology and neuropsychiatric disorders, while Soleno Therapeutics specializes in developing novel treatments for rare diseases. The acquisition is built around Soleno’s VYKAT XR, an FDA-approved therapy for hyperphagia associated with Prader-Willi syndrome (PWS), a genetic disorder affecting roughly 10,000 people in the United States.

This development matters because it integrates a high-growth asset into Neurocrine’s existing commercial infrastructure. VYKAT XR showed strong market uptake following its 2025 launch, contributing $92 million in the final quarter of that year alone. By absorbing this therapy, Neurocrine diversifies its revenue streams and cements its leadership in the specialized endocrinology market. The move directly impacts the rare disease sector and the PWS patient community by leveraging Neurocrine’s larger medical and distribution networks to scale the drug’s reach. For investors and industry stakeholders, the deal signals continued consolidation within the rare disease landscape, where established players are willing to pay significant premiums for de-risked, revenue-generating assets. The successful integration of Soleno’s commercial operations is expected to enhance Neurocrine’s long-term shareholder value and accelerate its portfolio shift toward transformative, first-in-class medicines. The transaction is subject to customary closing conditions and regulatory approvals.